Secreted phospholipase A(2), lipoprotein hydrolysis, and atherosclerosis: integration with lipidomics

por Yamamoto, Kei, Isogai, Yuki, Sato, Hiroyasu, Taketomi, Yoshitaka, Murakami, Makoto
Publicado 2011

Effects of Fremanezumab on Medication Overuse in Japanese Chronic Migraine Patients: Post Hoc Analysis of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

por Imai, Noboru, Isogai, Yuki, Shibasaki, Yoshiyuki, Nakai, Masami, Ishida, Miki, Ning, Xiaoping, Koga, Nobuyuki
Publicado 2023

Group III secreted phospholipase A(2) transgenic mice spontaneously develop inflammation

por Sato, Hiroyasu, Taketomi, Yoshitaka, Isogai, Yuki, Masuda, Seiko, Kobayashi, Tetsuyuki, Yamamoto, Kei, Murakami, Makoto
Publicado 2009

Long-Term Safety and Tolerability of Fremanezumab for Migraine Preventive Treatment in Japanese Outpatients: A Multicenter, Randomized, Open-Label Study

por Sakai, Fumihiko, Suzuki, Norihiro, Ning, Xiaoping, Ishida, Miki, Usuki, Chiharu, Iba, Katsuhiro, Isogai, Yuki, Koga, Nobuyuki
Publicado 2021

Fremanezumab for Chronic Migraine Prevention in Japanese Patients: Subgroup Analysis from Two International Trials

por Saigoh, Kazumasa, Takeshima, Takao, Nakai, Masami, Shibasaki, Yoshiyuki, Ishida, Miki, Ning, Xiaoping, Barash, Steve, Isogai, Yuki, Koga, Nobuyuki
Publicado 2023

Fremanezumab for Episodic Migraine Prevention in Japanese Patients: Subgroup Analysis from Two International Trials

por Saigoh, Kazumasa, Takeshima, Takao, Nakai, Masami, Shibasaki, Yoshiyuki, Ishida, Miki, Ning, Xiaoping, Barash, Steve, Isogai, Yuki, Koga, Nobuyuki
Publicado 2023